Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers
Open Access
- 15 February 2014
- journal article
- clinical trial
- Published by Impact Journals, LLC in Oncotarget
- Vol. 5 (3), 587-598
- https://doi.org/10.18632/oncotarget.1782
Abstract
Epigenetic therapy is emerging as a potential therapy for solid tumors. To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment with the DNA methyltransferase inhibitor 5-azacitidine (AZA). Gene Set Enrichment Analysis demonstrated significant enrichment for immunomodulatory pathways in all three cancers (14.4-31.3%) including interferon signaling, antigen processing and presentation, and cytokines/chemokines. Strong upregulation of cancer testis antigens was also observed. An AZA IMmune gene set (AIMs) derived from the union of these immunomodulatory pathway genes classified primary tumors from all three types into “high” and “low” AIM gene expression subsets in tumor expression data from both TCGA and GEO. Samples from selected patient biopsies showed upregulation of AIM genes after treatment with epigenetic therapy. These results point to a broad immune stimulatory role for DNA demethylating drugs in multiple cancers.Keywords
This publication has 34 references indexed in Scilit:
- Harnessing the potential of epigenetic therapy to target solid tumorsJCI Insight, 2014
- Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transitionInternational Journal of Cancer, 2013
- Alterations of immune response of non-small cell lung cancer with AzacytidineOncotarget, 2013
- DNA methylation and nucleosome occupancy regulate the cancer germline antigen geneMAGEA11Epigenetics, 2013
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic ValuePLoS Medicine, 2013
- Prognostically relevant gene signatures of high-grade serous ovarian carcinomaJCI Insight, 2012
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escapeNature Medicine, 2012
- Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screenEpigenetics, 2012
- Limited Gene Activation in Tumor and Normal Epithelial Cells Treated with the DNA Methyltransferase Inhibitor 5-Aza-2′-deoxycytidinePublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Biological Effects of 5-Azacytidine in EukaryotesOncology, 1974